Active pharmaceutical ingredient (API) manufacturer SCI Pharmtech reported a 25.42% year-on-year increase in revenue for the second quarter. However, its gross profit margin dropped by nearly one percentage point to 27.49%. The company's core business profits grew by 50%, but net profit after tax decreased by 68.83% due to a high comparison base from insurance compensation in the same period last year. Earnings per share (EPS) for the quarter were NT$0.52, with a cumulative EPS of NT$0.89 for the first half of the year. Looking ahead, the company expects new production capacity to continue contributing, with epilepsy drugs projected to scale up production next year. A batch of Alzheimer's medication is scheduled for shipment in the fourth quarter, and orders for anti-opioid addiction and pain relief drugs are expected to be fulfilled next year, signaling an improving operational outlook.
Read more
